RemeGen Co., Ltd. (SHA:688331)

Market Cap	52.99B -17.6%
Revenue (ttm)	8.01B +286.2%
Net Income	5.82B
EPS	10.39
Shares Out	n/a
PE Ratio	9.32
Forward PE	21.68
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,448,539
Open	115.50
Previous Close	116.67
Day's Range	113.00 - 116.25
52-Week Range	75.03 - 157.80
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 30, 2026

About RemeGen

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease, rheumatoid arthritis, and myasthenia gravis; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of gastric cancer, urothelial carcinoma, breast cancer, and other tumors. It also develops p...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2008
• Employees: 3,145
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688331

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 8, 2026

Data Sources Report a data error